Department of Oncology, Lianyungang First People's Hospital, Lianyungang 222002, China.
Clin Transl Oncol. 2012 Jun;14(6):437-43. doi: 10.1007/s12094-012-0821-3.
To observe the dynamic changes of blood perfusion and hypoxic status with CT perfusion imaging and hypoxia imaging in patients of non-small-cell lung cancer (NSCLC) who were treated with recombinant human endostatin (RHES).
Fifteen previously untreated patients with histologically or cytologically confirmed NSCLC were enrolled. They were randomly divided into research group (n=10) and negative control group (n=5). The patients of the research group continuously used RHES for ten days, and simultaneously had CT perfusion imaging and hypoxia imaging performed on days 1, 5 and 10, respectively. The remaining 5(control) only had CT perfusion imaging and hypoxia imaging, without using RHES, on days 1, 5 and 10, respectively. According to the above results, we could obtain a "time window" during which RHES improves blood perfusion and hypoxia of lung cancer.
In the research group, after using RHES, capillary permeability surface (PS) and tumour to normal tissue (T/N) decreased at first, and then increased. Their lowest points occurred on about the fifth day with statistical significance compared with the first day (T/N, p=0.00; PS, p<0.01). Blood flow (BF) was first increased and then decreased. Its highest point occurred on about the fifth day with statistical significance compared with the first and tenth day (all p<0.01). The PS, BF and T/N peaked on the fifth day in the research group with statistical significance compared with the negative control group as well (all p<0.01). The above results suggested that RHES's "time window" was within about one week after administration.
RHES's "time window" is within about one week after administration, which provides an important experimental basis for combining RHES with radiotherapy in human tumours.
观察重组人血管内皮抑制素（rhES）治疗非小细胞肺癌（NSCLC）患者时 CT 灌注成像和缺氧成像的血供和缺氧状态的动态变化。
纳入 15 例经组织学或细胞学证实的 NSCLC 初治患者。随机分为研究组（n=10）和阴性对照组（n=5）。研究组连续使用 rhES 10 天，分别于第 1、5、10 天进行 CT 灌注成像和缺氧成像；其余 5 例（对照组）仅于第 1、5、10 天分别进行 CT 灌注成像和缺氧成像，不使用 rhES。根据上述结果，可以获得 rhES 改善肺癌血供和缺氧的“时间窗”。
研究组使用 rhES 后，毛细血管通透性表面积（PS）和肿瘤与正常组织（T/N）先降低后升高，第 5 天最低，与第 1 天比较差异有统计学意义（T/N，p=0.00；PS，p<0.01）。血流（BF）先升高后降低，第 5 天最高，与第 1 天和第 10 天比较差异有统计学意义（均 p<0.01）。研究组 PS、BF 和 T/N 于第 5 天达到峰值，与阴性对照组比较差异有统计学意义（均 p<0.01）。提示 rhES 的“时间窗”约为用药后 1 周内。
rhES 的“时间窗”约为用药后 1 周内，为 rhES 与放疗联合治疗人类肿瘤提供了重要的实验依据。
